GW Pharmaceuticals PLC Sponsored ADR(NASDAQ : GWPH)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading GWPH News...
Health Technology » Pharmaceuticals Other
|SHPG||Shire PLC Sponsored ADR||-7.91%||166.03||9.9%||$682.82m|
|VRX||Valeant Pharmaceuticals International, Inc.||-8.85%||20.28||7.1%||$590.12m|
|PRGO||Perrigo Co. Plc||-4.44%||90.97||4.0%||$246.55m|
|ENDP||Endo International Plc||-6.25%||14.85||4.1%||$131.38m|
|JAZZ||Jazz Pharmaceuticals Plc||-4.90%||137.90||2.7%||$122.88m|
|ICPT||Intercept Pharmaceuticals, Inc.||-7.35%||142.92||13.8%||$89.19m|
|HZNP||Horizon Pharma plc||-6.82%||16.25||9.7%||$64.47m|
|UTHR||United Therapeutics Corporation||-3.01%||102.11||19.5%||$61.35m|
|GWPH||GW Pharmaceuticals PLC Sponsored ADR||-6.54%||83.31||12.2%||$37.71m|
GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.